Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMD-3866 in Chemotherapy-induced Peripheral Neuropathy (CIPN)
NCT07072468Phase 2Recruiting
- Sponsor
- VM Therapeutics
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VMD-3866 in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by VM Therapeutics. Primary endpoints: Numeric Pain Rating Scale at 8 days and Adverse Events at 1 month. Started Dec 2025; status: recruiting.
02
Drugs
VMD-3866
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07072468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072468.